Eurosurv. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term ca

[tetano]

• Clara Mazagatos[SUP]1[/SUP] , Susana Monge[SUP]2[/SUP] , Carmen Olmedo[SUP]3[/SUP] , Lorena Vega[SUP]1[/SUP] , Pilar Gallego[SUP]1[/SUP] , Elisa Martín-Merino[SUP]4[/SUP] , María José Sierra[SUP]2[/SUP] , Aurora Limia[SUP]3[/SUP] , Amparo Larrauri[SUP]1[/SUP] , Working Group for the surveillance and control of COVID-19 in Spain[SUP]5[/SUP]

Residents in long-term care facilities (LTCF) experienced a large morbidity and mortality during the COVID-19 pandemic in Spain and were prioritised for early COVID-19 vaccination. We used the screening method and population-based data sources to obtain estimates of mRNA COVID-19 vaccine effectiveness for elderly LTCF residents. The estimates were 71% (95% CI: 56–82%), 88% (95% CI: 75–95%), and 97% (95% CI: 92-99%), against SARS-CoV-2 infections (symptomatic and asymptomatic), and COVID-19 hospitalisations and deaths, respectively.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.24.2100452#html_fulltext